Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name ANRIL
   Synonyms CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS
   Region GRCh38_9:21994778-22121097    Sequence
   Ensembl ENSG00000240498
   RefSeq NR_003529
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name renal cell carcinoma
   ICD-0-3 C64.9  
   Methods qPCR, RNAi, Western blot, Cell migration and invasion assay, CCK-8 assay etc.
   Sample RCC tissues, cell lines (786-O, A498, caki-1 and caki-2, and HEK-293T)
   Expression Pattern up-regulated
   Function Description

ANRIL was highly expressed in RCC tissues and RCC cell lines. ANRIL significantly promoted cell proliferation, migration, invasion and EMT but inhibited cell apoptosis. Additionally, the expression levels of B-catenin, Ki-67, glycogen synthase kinase 3B (GSK-3B), phosphorylated GSK-3B, T cell transcription factor 4 (TCF-4) and leukemia enhancer factor 1 (LEF-1) were all markedly up-regulated by ANRIL.

   Pubmed ID 28251886
   Year 2017
   Title Highly Expressed Antisense Non-coding RNA in the INK4 Locus Promotes 5 Growth and Invasion of Renal Clear Carcinoma Cells Via the B-catenin Pathway.
   External Links
   Links for  ANRIL GenBank       HGNC       lncrnadb       Noncode
   Links for  renal cell carcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.